From the decision analysis came an agreement that reimbursement for an orphan drug should be based primarily on its effect on health-related quality of life, its effectiveness, and the availability of other treatment options.
Analyzing various factors related to orphan drugs, a group of stakeholders has determined which and how each criteria should factor into decisions being made for reimbursement of these drugs to treat rare diseases.
From the decision analysis came an agreement that reimbursement for an orphan medicinal product (OMP) should be based primarily on its effect on health-related quality of life, its effectiveness, and the availability of other treatment options.
“These criteria and their relative importance weights can serve as a starting point to guide and inspire health authorities and the rest of decision makers involved to promote the development of a specific framework of multicriteria evaluation and move forward to a structured plan for the evaluation of OMPs,” wrote the researchers.
The group consisted of 28 stakeholders including physicians, hospital pharmacists, health economists, patient representatives, and health authorities.
Thirteen criteria related to the patient population, the disease state, treatment, and economic evaluation were included in the review. Based on the analysis, the group identified 9 criteria that should be considered when making decisions about reimbursement:
The remaining 4 criteria—economic burden of disease, cost of treatment, cost-effectiveness, and safety—were determined to have a relative importance of less than 3%.
“According to the results obtained, preference was given to a scenario that financed OMPs for diseases with a target population of lower prevalence, of nonpediatric age, and prioritizing the most severe pathologies,” explained the researchers. “It was important that the orphan drug presented nonserious versus serious adverse events and that no other treatment options were available. In terms of the efficacy criteria, treatments that were curative or that significantly increased survival were preferred over other benefits, as were treatments that had high-quality evidence from controlled clinical trials with comparators.”
The group added that treatments that improved health-related quality of life while avoiding higher costs associated with the disease were prioritized.
Notably, the multistakeholder panel did place a higher weight on cost for treatments for nonpediatric patient populations.
Reference
Andrés‐Nogales F, Cruz E, Calleja M, et al. A multi‐stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU‐MCDA study). Orphanet J Rare Dis. Published online August 17, 2021. doi:10.1186/s13045-021-01135-w
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More